Skip to main content
. 2022 Aug 24;10(8):e004006. doi: 10.1136/jitc-2021-004006

Figure 6.

Figure 6

Combined HBO with teniposide chemotherapy sensitized tumor response to PD-1 antibody. (A) Schematic illustration of anti-PD-1 sensitization experiments in vivo. Mice with subcutaneously established tumors were intraperitoneally injected with DMSO (Ctrl) and teniposide (10 mg/kg) twice at indicated time points, and HBO therapy was administrated after teniposide chemotherapy in the HBO+teniposide+PD-1 combination group for a total of five times. PD-1 antibody (200 µg per mouse) was intraperitoneally injected every 3 days at indicated time points (n=5 per group). (B–D) Tumor growth curves of Hepa1-6 (B), MC38 (C) and B16 (D) bearing mice during anti-PD-1 sensitization experiments. (E) Schematic diagram of the combination therapy based on HBO and teniposide. *P<0.05, **P<0.01, ***P<0.001. cGAS, cyclic GMP-AMP synthase; CTL, cytotoxic T lymphocyte; Ctrl, control; DC, dendritic cell; DMSO, Dimethyl sulfoxide; HBO, hyperbaric oxygen; IFN-I, interferon type I; IFN-γ, interferon γ; IRF3, interferon regulatory factor 3; NF-κB, nuclear factor kappa-B; PD1, programmed cell death protein-1; STING, stimulator of interferon genes; Teni, teniposide; TNF-α, tumor necrosis factor-α.